Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB clinical trials

A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have de novo metastatic disease. "The FLIPPER Study"

This study, called "The FLIPPER Study," is looking at new treatments for women with breast cancer that has spread. It compares a standard drug (Faslodex) with a new combination of Faslodex and another drug (Palbociclib) to see if it works better at stopping the cancer from growing.